DCTH Key Statistics, Chart & Performance
The current stock price of DCTH is 10.34 USD. In the past month the price increased by 4.23%. In the past year, price decreased by -9.93%.
DCTH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.23 | 218.96B | ||
| ISRG | INTUITIVE SURGICAL INC | 68.09 | 207.82B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.1 | 144.75B | ||
| SYK | STRYKER CORP | 27.91 | 140.55B | ||
| BDX | BECTON DICKINSON AND CO | 14.06 | 57.87B | ||
| IDXX | IDEXX LABORATORIES INC | 56.57 | 56.96B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.12 | 49.40B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 19.02 | 39.76B | ||
| RMD | RESMED INC | 25.5 | 36.85B | ||
| DXCM | DEXCOM INC | 36.24 | 26.29B | ||
| PODD | INSULET CORP | 63.25 | 20.33B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.48 | 18.40B |
Related stock screener links
About DCTH
Company Profile
Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. The company is headquartered in Queensbury, New York and currently employs 96 full-time employees. The company went IPO on 2000-10-19. The firm's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Company Info
DELCATH SYSTEMS INC
566 Queensbury Avenue
Queensbury NEW YORK 10019 US
CEO: Gerard Michel
Employees: 96
Phone: 15187438892
DELCATH SYSTEMS INC / DCTH FAQ
What does DELCATH SYSTEMS INC do?
Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. The company is headquartered in Queensbury, New York and currently employs 96 full-time employees. The company went IPO on 2000-10-19. The firm's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Can you provide the latest stock price for DELCATH SYSTEMS INC?
The current stock price of DCTH is 10.34 USD. The price increased by 1.27% in the last trading session.
Does DCTH stock pay dividends?
DCTH does not pay a dividend.
How is the ChartMill rating for DELCATH SYSTEMS INC?
DCTH has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
How is the market expecting DCTH stock to perform?
13 analysts have analysed DCTH and the average price target is 23.61 USD. This implies a price increase of 128.3% is expected in the next year compared to the current price of 10.34.
Can you provide the PE ratio for DCTH stock?
The PE ratio for DELCATH SYSTEMS INC (DCTH) is 1034. This is based on the reported non-GAAP earnings per share of 0.01 and the current share price of 10.34 USD.
What is the ownership structure of DELCATH SYSTEMS INC (DCTH)?
You can find the ownership structure of DELCATH SYSTEMS INC (DCTH) on the Ownership tab.
DCTH Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to DCTH. When comparing the yearly performance of all stocks, DCTH is a bad performer in the overall market: 76.58% of all stocks are doing better.
DCTH Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to DCTH. DCTH has an excellent financial health rating, but there are some minor concerns on its profitability.
DCTH Financial Highlights
Over the last trailing twelve months DCTH reported a non-GAAP Earnings per Share(EPS) of 0.01. The EPS increased by 100.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1.5% | ||
| ROA | 0.96% | ||
| ROE | 1.04% | ||
| Debt/Equity | 0 |
DCTH Forecast & Estimates
13 analysts have analysed DCTH and the average price target is 23.61 USD. This implies a price increase of 128.3% is expected in the next year compared to the current price of 10.34.
For the next year, analysts expect an EPS growth of 104.16% and a revenue growth 135.53% for DCTH